Corner Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Corner Therapeutics, Inc. - overview
Established
2020
Location
Watertown, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2020 by CEO Steven M. Altschuler, Jonathan Kagan, and Marian R. Neutra, Corner Therapeutics, Inc. , a.
k. a. Corner Therapeutics operates as an immunotherapy company that focuses on developing multi-purpose immunotherapies to address a virtually unbounded range of cancers and infectious diseases. In April 2024, Corner Therapeutics raised USD 54 million in a Series A funding led by Ziff Capital Partners, with participation from Cockrell Interests, Tanis Venture Management, and Sandia Holdings.
The company offers DC Hyperactivation, an immunotherapy platform that enhances dendritic cells' intelligence to generate robust T and B cell-mediated immunity for life. By leveraging hyperactivators, the platform stimulates inflammasome activation within living dendritic cells, leading to long-lasting memory T cell production and effective disease treatment. In addition, Corner Therapeutics utilizes a catalytic adjuvant platform to develop nucleic acid-based vaccines for infection prevention and cancer treatment. Unlike conventional mRNA-LNP vaccines, the platform enhances both cellular and humoral immunity, generating durable memory T cells and preserving antibody responses for lifelong immunity against diseases.
The company plans to use its proceeds from April 2024 funding to create vaccines that confer lifelong protection from cancer and infectious diseases.
Current Investors
Cockrell Interests, Ziff Capital Partners, Tanis Venture Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
https://cornertx.com/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Corner Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.